Source-grounded facts extracted from Voyager Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Voyager Therapeutics, Inc. reported first quarter 2026 results: revenue $2.6 million, net income $27.9 million.
“Collaboration revenue was $2.6 million for the three months ended March 31, 2026, compared to $6.5 million for the first quarter of 2025.”
Nathan Jorgensen was appointed as Chief Financial Officer at Voyager Therapeutics, Inc..
“On June 11, 2024, Voyager Therapeutics, Inc. (the “Company”) and Nathan Jorgensen entered into an employment agreement (the “Jorgensen Agreement”), pursuant to which Dr. Jorgensen agreed to serve as the Chief Financial Officer of the Company, with his employment to commence no later than July 8, 2024”
Voyager Therapeutics, Inc. reported first quarter 2024 results: revenue $19.5 million, net income $11.3 million.
“INDs for the GBA1 and Friedreich’s Ataxia gene therapy programs in 2025. First Quarter 2024 Financial Results ● Collaboration Revenues: Voyager had collaboration revenue of $19.5 million for the first quarter of 2024, compared to $150.5 million for the same period in 2023. The decrease was primarily due to the first quarter 2023 recognition of $69.5 million from”
Voyager Therapeutics, Inc. reported Q4 2023 results: revenue $90.1 million, net income $56.4 million.
“Voyager had collaboration revenue of $90.1 million for the fourth quarter of 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.